Enhancement of piperlongumine chemosensitivity by silencing heme oxygenase‑1 expression in cholangiocarcinoma cell lines

Talabnin,Chutima; Talabnin,Krajang; Wongkham,Sopit

doi:10.3892/ol.2020.11784

Enhancement of piperlongumine chemosensitivity by silencing heme oxygenase‑1 expression in cholangiocarcinoma cell lines

Authors:
- Chutima Talabnin
- Krajang Talabnin
- Sopit Wongkham
View Affiliations

Affiliations: School of Chemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand, School of Pathology, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Published online on: June 26, 2020 https://doi.org/10.3892/ol.2020.11784
Pages: 2483-2492

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Piperlongumine (PL) produces reactive oxygen species (ROS) and induces G2/M‑phase arrest in cholangiocarcinoma (CCA) cells via the JNK/ERK pathway. A differential response to PL was observed among all CCA cell lines However, the underlying mechanisms have remained to be fully elucidated. The aim of the present study was to investigate the molecular mechanisms of PL‑induced heme oxygenase‑1 (HO‑1) expression in CCA cell lines. The anti‑proliferative action of PL in the CCA cell lines KKU‑100 and KKU‑213A was analyzed using sulforhodamine B assays. Reverse transcription‑quantitative PCR and western blot analyses were used to examine mRNA and protein expression. HO‑1 inhibition was achieved using the chemical inhibitor zinc protophoryn or specific small interfering RNA to HO‑1. Intracellular ROS was detected using a 2',7'‑dichlorodihydrofluorescein diacetate fluorescence assay. High expression of phase‑II detoxification enzymes, including NADPH quinone oxidoreductase‑1, heme oxygenase‑1, superoxide dismutases and aldo‑keto reductase 1 subunits C‑1 and 3, were detected in the KKU‑100 cell line. Of the CCA cell lines tested, KKU‑100 was the least sensitive to PL. Dose‑dependent upregulation of HO‑1 expression via PI3K/Akt activation was detected in PL‑treated CCA cells. Inhibition of HO‑1 eliminated the antioxidant defense mechanisms, leading to increased anti‑cancer activity of PL in the CCA cell lines via an increase in intracellular ROS levels and apoptotic protein expression. These observations indicated that HO‑1 inhibition had a chemosensitizing effect on CCA to PL.

View Figures

View References

1	Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, et al British Society of Gastroenterology, : Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bhudhisawasdi V, Talabnin C, Pugkhem A, Khuntikeo N, Seow OT, Chur-in S, Pairojkul C and Wongkham S: Evaluation of postoperative adjuvant chemotherapy for intrahepatic cholangiocarcinoma patients undergoing R1 and R2 resections. Asian Pac J Cancer Prev. 13:169–174. 2012.PubMed/NCBI
3	Dhanasekaran R, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V and Cabrera R: Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 29:1259–1267. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y and Nimura Y: Evolution of surgical treatment for perihilar cholangiocarcinoma: A single-center 34-year review of 574 consecutive resections. Ann Surg. 258:129–140. 2013. View Article : Google Scholar : PubMed/NCBI
5	Nagorney DM, Donohue JH, Farnell MB, Schleck CD and Ilstrup DM: Outcomes after curative resections of cholangiocarcinoma. Arch Surg. 128:871–879. 1993. View Article : Google Scholar : PubMed/NCBI
6	Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 16 (Suppl 2):ii93–ii96. 2005. View Article : Google Scholar : PubMed/NCBI
7	Fodale V, Pierobon M, Liotta L and Petricoin E: Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? Cancer J. 17:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
8	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
9	Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 7:97–110. 2004. View Article : Google Scholar : PubMed/NCBI
10	Gorrini C, Harris IS and Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
11	Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW and Wang YZ: The xc-cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: Use of sulfasalazine. Cancer Chemother Pharmacol. 64:463–472. 2009. View Article : Google Scholar : PubMed/NCBI
12	Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, et al: Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer. Breast Cancer Res Treat. 132:215–223. 2012. View Article : Google Scholar : PubMed/NCBI
13	Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liu JM, Pan F, Li L, Liu OR, Chen Y, Xiong XX, Cheng K, Yu SB, Shi Z, Yu CH, et al: Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun. 437:87–93. 2013. View Article : Google Scholar : PubMed/NCBI
15	Thongsom S, Suginta W, Lee KJ, Choe H and Talabnin C: Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway. Apoptosis. 22:1473–1484. 2017. View Article : Google Scholar : PubMed/NCBI
16	Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 475:231–234. 2011. View Article : Google Scholar : PubMed/NCBI
17	Maines MD and Abrahamsson PA: Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology. 47:727–733. 1996. View Article : Google Scholar : PubMed/NCBI
18	Goodman AI, Choudhury M, da Silva JL, Schwartzman ML and Abraham NG: Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med. 214:54–61. 1997. View Article : Google Scholar : PubMed/NCBI
19	Yin H, Fang J, Liao L, Maeda H and Su Q: Upregulation of heme oxygenase-1 in colorectal cancer patients with increased circulation carbon monoxide levels, potentially affects chemotherapeutic sensitivity. BMC Cancer. 14:4362014. View Article : Google Scholar : PubMed/NCBI
20	Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Kukongviriyapan U and Buranrat B: Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One. 7:e349942012. View Article : Google Scholar : PubMed/NCBI
21	Kongpetch S, Puapairoj A, Ong CK, Senggunprai L, Prawan A, Kukongviriyapan U, Chan-On W, Siew EY, Khuntikeo N, Teh BT, et al: Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice. Cell Prolif. 49:90–101. 2016. View Article : Google Scholar : PubMed/NCBI
22	Furfaro AL, Piras S, Passalacqua M, Domenicotti C, Parodi A, Fenoglio D, Pronzato MA, Marinari UM, Moretta L, Traverso N, et al: HO-1 up-regulation: A key point in high-risk neuroblastoma resistance to bortezomib. Biochim Biophys Acta. 1842:613–622. 2014. View Article : Google Scholar : PubMed/NCBI
23	Lv X, Song DM, Niu YH and Wang BS: Inhibition of heme oxygenase-1 enhances the chemosensitivity of laryngeal squamous cell cancer Hep-2 cells to cisplatin. Apoptosis. 21:489–501. 2016. View Article : Google Scholar : PubMed/NCBI
24	Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C and Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 11:3392–3397. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sripa B, Seubwai W, Vaeteewoottacharn K, Sawanyawisuth K, Silsirivanit A, Kaewkong W, Muisuk K, Dana P, Phoomak C, Lert-Itthiporn W, et al: Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Hum Cell. Mar 23–2020.(Epub ahead of print). doi: 10.1007/s13577-020-00334-w. View Article : Google Scholar : PubMed/NCBI
26	Voigt W: Sulforhodamine B assay and chemosensitivity. Methods Mol Med. 110:39–48. 2005.PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Labbé RF, Vreman HJ and Stevenson DK: Zinc protoporphyrin: A metabolite with a mission. Clin Chem. 45:2060–2072. 1999. View Article : Google Scholar : PubMed/NCBI
29	Wang S, Avery JE, Hannafon BN, Lind SE and Ding WQ: Zinc protoporphyrin suppresses cancer cell viability through a heme oxygenase-1-independent mechanism: The involvement of the Wnt/β-catenin signaling pathway. Biochem Pharmacol. 85:1611–1618. 2013. View Article : Google Scholar : PubMed/NCBI
30	Liu YS, Li HS, Qi DF, Zhang J, Jiang XC, Shi K, Zhang XJ and Zhang XH: Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin. World J Gastroenterol. 20:8572–8582. 2014. View Article : Google Scholar : PubMed/NCBI
31	Cheng CC, Guan SS, Yang HJ, Chang CC, Luo TY, Chang J and Ho AS: Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer. J Biomed Sci. 23:182016. View Article : Google Scholar : PubMed/NCBI
32	Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, Galarreta CM and Cuadrado A: Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 279:8919–8929. 2004. View Article : Google Scholar : PubMed/NCBI
33	Chen HH, Chen YT, Huang YW, Tsai HJ and Kuo CC: 4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling. Free Radic Biol Med. 52:1054–1066. 2012. View Article : Google Scholar : PubMed/NCBI
34	Lee HN, Jin HO, Park JA, Kim JH, Kim JY, Kim B, Kim W, Hong SE, Lee YH, Chang YH, et al: Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine. Mol Cells. 38:327–335. 2015. View Article : Google Scholar : PubMed/NCBI
35	Wang F, Mao Y, You Q, Hua D and Cai D: Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway. Int J Immunopathol Pharmacol. 28:362–373. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zhou L, Li M, Yu X, Gao F and Li W: Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells. Int J Biol Sci. 15:826–837. 2019. View Article : Google Scholar : PubMed/NCBI
37	Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M and Miyagawa SI: Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Oncol Rep. 39:843–850. 2018.PubMed/NCBI
38	Yoon H, Min JK, Lee JW, Kim DG and Hong HJ: Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun. 405:333–337. 2011. View Article : Google Scholar : PubMed/NCBI
39	Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ and Loilome W: Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol. 34:3637–3648. 2013. View Article : Google Scholar : PubMed/NCBI
40	Chen HH, Chen YT and Huang YW: 4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling. Free Radic Biol Med. 52:1054–1066. 2012. View Article : Google Scholar : PubMed/NCBI
41	Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR and Schäfer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
42	Huang WC and Hung MC: Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc. 108:180–194. 2009. View Article : Google Scholar : PubMed/NCBI
43	Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S and Tungpradubkul S: Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int. 9:32009. View Article : Google Scholar : PubMed/NCBI
44	Berberat PO, Dambrauskas Z, Gulbinas A, Giese TG, Kunzli B, Autschbach F, Meuer S, Büchler MW and Friess H: Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res. 11:3790–3798. 2005. View Article : Google Scholar : PubMed/NCBI